Ankylosing Spondylitis Market Research Report by Drug (Cimzia, Cosentyx, and Enbrel), by Type of Molecule (Biologics and Small Molecules), by Mechanism Of Action, by Route Of Administration, by Dosage Forms, by End User, by Region (Americas, Asia-Paci

Ankylosing Spondylitis Market Research Report by Drug (Cimzia, Cosentyx, and Enbrel), by Type of Molecule (Biologics and Small Molecules), by Mechanism Of Action, by Route Of Administration, by Dosage Forms, by End User, by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2026 - Cumulative Impact of COVID-19

The Global Ankylosing Spondylitis Market size was estimated at USD 4,112.97 million in 2020 and expected to reach USD 4,433.31 million in 2021, at a CAGR 8.12% to reach USD 6,573.00 million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.


Market Segmentation & Coverage:

This research report categorizes the Ankylosing Spondylitis to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Drug , the market was studied across Cimzia, Cosentyx, Enbrel, Humira, Remicade, and Simponi.

Based on Type of Molecule, the market was studied across Biologics and Small Molecules.

Based on Mechanism Of Action, the market was studied across COX Inhibitors and TNF Inhibitors.

Based on Route Of Administration, the market was studied across Oral and Parenteral.

Based on Dosage Forms, the market was studied across Liquid and Solid.

Based on End User , the market was studied across Clinics and Hospitals.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Ankylosing Spondylitis Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Ankylosing Spondylitis Market, including Abbvie Inc., Amgen Inc., Biothera Pharmaceuticals, Inc., Bristol-Myers Squibb, C.H. Boehringer Sohn AG & Ko. KG, Cadila Healthcare Limited, Celgene Corporation, Celltrion, Eisai Co., Ltd, Eli Lilly and Company, F. Hoffmann-La Roche AG, Hetero Drugs Limited, Izana Bioscience, Johnson & Johnson Services, Inc., Merck & Co., Inc, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc, Reliance Life Sciences, Samsung Bioepis Co., Ltd., Sandoz International GmbH, Sanofi SA, Shanghai Pharmaceuticals Holding Co., Ltd., Trinity Biotech Ireland, UCB Inc., and Xian Janssen Pharmaceutical Ltd.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Ankylosing Spondylitis Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Ankylosing Spondylitis Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Ankylosing Spondylitis Market?
4. What is the competitive strategic window for opportunities in the Global Ankylosing Spondylitis Market?
5. What are the technology trends and regulatory frameworks in the Global Ankylosing Spondylitis Market?
6. What is the market share of the leading vendors in the Global Ankylosing Spondylitis Market?
7. What modes and strategic moves are considered suitable for entering the Global Ankylosing Spondylitis Market?


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
3.1. Introduction
4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19
5. Market Dynamics
5.1. Introduction
5.2. Drivers
5.2.1. Increasing incidences of ankylosing spondylitis
5.2.2. Growing awareness about diagnostics and treatments for the disease
5.3. Restraints
5.3.1. Expiry patent of the drugs
5.4. Opportunities
5.4.1. Increase in research and development expenditure for the treatment of the spondylitis
5.4.2. Introduction of the biosimilars
5.5. Challenges
5.5.1. High cost of treatment and limited of skilled surgeons and physiotherapists
6. Ankylosing Spondylitis Market, by Drug
6.1. Introduction
6.2. Cimzia
6.3. Cosentyx
6.4. Enbrel
6.5. Humira
6.6. Remicade
6.7. Simponi
7. Ankylosing Spondylitis Market, by Type of Molecule
7.1. Introduction
7.2. Biologics
7.3. Small Molecules
8. Ankylosing Spondylitis Market, by Mechanism Of Action
8.1. Introduction
8.2. COX Inhibitors
8.3. TNF Inhibitors
9. Ankylosing Spondylitis Market, by Route Of Administration
9.1. Introduction
9.2. Oral
9.3. Parenteral
10. Ankylosing Spondylitis Market, by Dosage Forms
10.1. Introduction
10.2. Liquid
10.3. Solid
11. Ankylosing Spondylitis Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Hospitals
12. Americas Ankylosing Spondylitis Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Ankylosing Spondylitis Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
14. Europe, Middle East & Africa Ankylosing Spondylitis Market
14.1. Introduction
14.2. France
14.3. Germany
14.4. Italy
14.5. Netherlands
14.6. Qatar
14.7. Russia
14.8. Saudi Arabia
14.9. South Africa
14.10. Spain
14.11. United Arab Emirates
14.12. United Kingdom
15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.1.1. Quadrants
15.1.2. Business Strategy
15.1.3. Product Satisfaction
15.2. Market Ranking Analysis
15.3. Market Share Analysis, By Key Player
15.4. Competitive Scenario
15.4.1. Merger & Acquisition
15.4.2. Agreement, Collaboration, & Partnership
15.4.3. New Product Launch & Enhancement
15.4.4. Investment & Funding
15.4.5. Award, Recognition, & Expansion
16. Company Usability Profiles
16.1. Abbvie Inc.
16.2. Amgen Inc.
16.3. Biothera Pharmaceuticals, Inc.
16.4. Bristol-Myers Squibb
16.5. C.H. Boehringer Sohn AG & Ko. KG
16.6. Cadila Healthcare Limited
16.7. Celgene Corporation
16.8. Celltrion
16.9. Eisai Co., Ltd
16.10. Eli Lilly and Company
16.11. F. Hoffmann-La Roche AG
16.12. Hetero Drugs Limited
16.13. Izana Bioscience
16.14. Johnson & Johnson Services, Inc.
16.15. Merck & Co., Inc
16.16. Novartis AG
16.17. Pfizer Inc.
16.18. Regeneron Pharmaceuticals, Inc
16.19. Reliance Life Sciences
16.20. Samsung Bioepis Co., Ltd.
16.21. Sandoz International GmbH
16.22. Sanofi SA
16.23. Shanghai Pharmaceuticals Holding Co., Ltd.
16.24. Trinity Biotech Ireland
16.25. UCB Inc.
16.26. Xian Janssen Pharmaceutical Ltd
17. Appendix
17.1. Discussion Guide
17.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, 2020 VS 2026 (USD MILLION)
FIGURE 2. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 3. GLOBAL ANKYLOSING SPONDYLITIS MARKET: MARKET DYNAMICS
FIGURE 4. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2020 VS 2026 (%)
FIGURE 5. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2020 VS 2026 (USD MILLION)
FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2026
FIGURE 7. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CIMZIA, 2018-2026 (USD MILLION)
FIGURE 8. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CIMZIA, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 9. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COSENTYX, 2018-2026 (USD MILLION)
FIGURE 10. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COSENTYX, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 11. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ENBREL, 2018-2026 (USD MILLION)
FIGURE 12. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ENBREL, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 13. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HUMIRA, 2018-2026 (USD MILLION)
FIGURE 14. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HUMIRA, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 15. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REMICADE, 2018-2026 (USD MILLION)
FIGURE 16. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REMICADE, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 17. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SIMPONI, 2018-2026 (USD MILLION)
FIGURE 18. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SIMPONI, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 19. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2020 VS 2026 (%)
FIGURE 20. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2020 VS 2026 (USD MILLION)
FIGURE 21. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2026
FIGURE 22. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, 2018-2026 (USD MILLION)
FIGURE 23. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 24. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, 2018-2026 (USD MILLION)
FIGURE 25. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 26. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2020 VS 2026 (%)
FIGURE 27. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2020 VS 2026 (USD MILLION)
FIGURE 28. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2026
FIGURE 29. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COX INHIBITORS, 2018-2026 (USD MILLION)
FIGURE 30. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COX INHIBITORS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 31. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2026 (USD MILLION)
FIGURE 32. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 33. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 VS 2026 (%)
FIGURE 34. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 VS 2026 (USD MILLION)
FIGURE 35. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2026
FIGURE 36. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2026 (USD MILLION)
FIGURE 37. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 38. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PARENTERAL, 2018-2026 (USD MILLION)
FIGURE 39. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PARENTERAL, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 40. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2020 VS 2026 (%)
FIGURE 41. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2020 VS 2026 (USD MILLION)
FIGURE 42. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2026
FIGURE 43. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY LIQUID, 2018-2026 (USD MILLION)
FIGURE 44. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY LIQUID, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 45. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLID, 2018-2026 (USD MILLION)
FIGURE 46. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLID, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 47. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2020 VS 2026 (%)
FIGURE 48. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2020 VS 2026 (USD MILLION)
FIGURE 49. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2026
FIGURE 50. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CLINICS, 2018-2026 (USD MILLION)
FIGURE 51. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CLINICS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 52. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, 2018-2026 (USD MILLION)
FIGURE 53. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 54. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 55. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 56. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 57. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 58. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 59. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 60. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 61. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 62. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 63. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 64. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 65. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 66. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 67. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 68. SINGAPORE ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 69. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 70. TAIWAN ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 71. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 72. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 73. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 74. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 75. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 76. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 77. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 78. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 79. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 80. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 81. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 82. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 83. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 84. GLOBAL ANKYLOSING SPONDYLITIS MARKET: FPNV POSITIONING MATRIX
FIGURE 85. GLOBAL ANKYLOSING SPONDYLITIS MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 86. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ANKYLOSING SPONDYLITIS MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL ANKYLOSING SPONDYLITIS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 4. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG , 2018-2026 (USD MILLION)
TABLE 5. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CIMZIA, BY REGION, 2018-2026 (USD MILLION)
TABLE 6. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COSENTYX, BY REGION, 2018-2026 (USD MILLION)
TABLE 7. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ENBREL, BY REGION, 2018-2026 (USD MILLION)
TABLE 8. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HUMIRA, BY REGION, 2018-2026 (USD MILLION)
TABLE 9. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REMICADE, BY REGION, 2018-2026 (USD MILLION)
TABLE 10. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SIMPONI, BY REGION, 2018-2026 (USD MILLION)
TABLE 11. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2026 (USD MILLION)
TABLE 12. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2026 (USD MILLION)
TABLE 13. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2026 (USD MILLION)
TABLE 14. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2026 (USD MILLION)
TABLE 15. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COX INHIBITORS, BY REGION, 2018-2026 (USD MILLION)
TABLE 16. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2026 (USD MILLION)
TABLE 17. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD MILLION)
TABLE 18. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY REGION, 2018-2026 (USD MILLION)
TABLE 19. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2026 (USD MILLION)
TABLE 20. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2026 (USD MILLION)
TABLE 21. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY LIQUID, BY REGION, 2018-2026 (USD MILLION)
TABLE 22. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLID, BY REGION, 2018-2026 (USD MILLION)
TABLE 23. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER , 2018-2026 (USD MILLION)
TABLE 24. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CLINICS, BY REGION, 2018-2026 (USD MILLION)
TABLE 25. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2026 (USD MILLION)
TABLE 26. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 27. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 28. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 29. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 30. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 31. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 32. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 33. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 34. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 35. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 36. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 37. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 38. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 39. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 40. SINGAPORE ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 41. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 42. TAIWAN ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 43. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 44. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 45. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 46. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 47. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 48. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 49. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 50. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 51. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 52. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 53. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 54. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 55. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 56. GLOBAL ANKYLOSING SPONDYLITIS MARKET: SCORES
TABLE 57. GLOBAL ANKYLOSING SPONDYLITIS MARKET: BUSINESS STRATEGY
TABLE 58. GLOBAL ANKYLOSING SPONDYLITIS MARKET: PRODUCT SATISFACTION
TABLE 59. GLOBAL ANKYLOSING SPONDYLITIS MARKET: RANKING
TABLE 60. GLOBAL ANKYLOSING SPONDYLITIS MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 61. GLOBAL ANKYLOSING SPONDYLITIS MARKET: MERGER & ACQUISITION
TABLE 62. GLOBAL ANKYLOSING SPONDYLITIS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 63. GLOBAL ANKYLOSING SPONDYLITIS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 64. GLOBAL ANKYLOSING SPONDYLITIS MARKET: INVESTMENT & FUNDING
TABLE 65. GLOBAL ANKYLOSING SPONDYLITIS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 66. GLOBAL ANKYLOSING SPONDYLITIS MARKET: LICENSE & PRICING

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook